Avalo Therapeutics, Inc.
AVTX
$19.41
-$0.04-0.21%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -86.62% | -86.62% | -86.62% | -76.59% | -45.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.62% | -86.62% | -86.62% | -76.59% | -45.35% |
| Cost of Revenue | 67.63% | 90.29% | 131.38% | 215.88% | 632.36% |
| Gross Profit | -70.04% | -94.12% | -137.86% | -241.55% | -808.84% |
| SG&A Expenses | 33.27% | 23.54% | 32.82% | 47.09% | 57.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.86% | 56.08% | 76.67% | 107.54% | 163.39% |
| Operating Income | -51.87% | -57.33% | -78.43% | -112.37% | -170.98% |
| Income Before Tax | -117.31% | -215.65% | -123.03% | -1,151.78% | -27.29% |
| Income Tax Expenses | 37.90% | 46.96% | 44.74% | 1,755.56% | 853.85% |
| Earnings from Continuing Operations | -117.10% | -216.06% | -122.78% | -1,155.06% | -27.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.10% | -216.06% | -122.78% | -1,155.06% | -27.59% |
| EBIT | -51.87% | -57.33% | -78.43% | -112.37% | -170.98% |
| EBITDA | -52.63% | -57.73% | -78.32% | -112.08% | -171.15% |
| EPS Basic | 15.48% | -110.42% | 81.58% | 77.93% | 91.69% |
| Normalized Basic EPS | -92.92% | -258.55% | 94.15% | 91.70% | 98.21% |
| EPS Diluted | 49.64% | 48.68% | 85.36% | 84.98% | 88.56% |
| Normalized Diluted EPS | -5.98% | -451.48% | 94.26% | 91.86% | 96.73% |
| Average Basic Shares Outstanding | 158.45% | 27.15% | 33.86% | 48.94% | 47.02% |
| Average Diluted Shares Outstanding | 126.49% | 15.02% | 18.37% | 27.17% | 67.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |